Vimarsana
Biggest News Aggregation in the World

Drug Development Unit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Drug Development Unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Drug Development Unit Today - Breaking & Trending Today

Kirkcaldy MP joins call for debate on vaccine link to excess deaths - Vimarsana News

Kirkcaldy MP joins call for debate on vaccine link to excess deaths

Kirkcaldy MP Neale Hanvey has backed calls from a Tory MP expelled for sharing Covid conspiracy theories for debate on excess deaths.

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit - Vimarsana News

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

Preclinical and Clinical Presentations Include Update on FRAME Study Low-Grade Serous Ovarian Cancer Efficacy Data ...

2023-09-07 | NDAQ:ONCT | Press Release | Oncternal Therapeutics Inc - Vimarsana News

2023-09-07 | NDAQ:ONCT | Press Release | Oncternal Therapeutics Inc

(2023-09-07 | NDAQ:ONCT) Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

Dr Minchom on the Safety of Subcutaneous Amivantamab in Advanced Solid Tumors - Vimarsana News

Dr Minchom on the Safety of Subcutaneous Amivantamab in Advanced Solid Tumors

Anna R. Minchom MD, BCh, MB, MRCP, discusses the safety and recommended phase 2 doses of subcutaneous amivantamab-vmjw for patients with advanced solid tumors in the phase 1b PALOMA trial.

Targeted Therapy Developed in FCS Clinical Trials Transforming Cancer Treatment For Adult Patients with Diffuse Large B-cell Lymphoma - Vimarsana News

Targeted Therapy Developed in FCS Clinical Trials Transforming Cancer Treatment For Adult Patients with Diffuse Large B-cell Lymphoma

Florida Cancer Specialists & Research Institute, LLC released a case study outlining the evolution of a newly FDA-approved first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma.